Century Therapeutics, Inc. is a leading biotechnology company that is setting the rhythm in defining the future of cell therapy. The company's primary area of focus is on developing transformative cell therapies for cancer, using purpose-built iPSC platforms, with the goal of improving and saving lives.
Founded in 2019 and based in Philadelphia, Century stands out in its sophisticated and precise approach to oncology treatment. Its unique and innovative process involves programming induced pluripotent stem cells (iPSCs), which are adult cells that have been genetically reprogrammed back into an embryonic-like pluripotent state. By harnessing and appropriating these iPSCs, Century can manufacture any type of cell in the human body. The resultant cells have the potential to treat a variety of diseases, but Century's primary focus is on developing allogeneic cell therapies for patients suffering from cancer.
Unlike other cell therapies that are derived from the patients themselves or donors and can only be used once, Century's iPSC-derived therapies are "off-the-shelf," which means they can be mass produced and made readily available to patients who need them. This removes many logistical issues and reduces the production time and costs, making the therapies potentially more affordable and accessible.
Century's unique IPSC platform and the tremendous promise it holds in the oncology area has attracted a lot of attention in the biotech world. The company has successfully secured investment from high-profile entities such as Fujifilm Corporation and Versant Ventures.
Currently, Century Therapeutics is developing multiple "off-the-shelf" products in both the immune-oncology and hematologic malignancy spaces. They are also exploring the development of iPSC-derived chimeric antigen receptor T (CAR-T) cell therapies, which have previously shown incredible successes in treating certain types of cancers.
In a relatively short time, Century has made remarkable strides in cell and gene therapy, contributing major innovative breakthroughs. They have carved out a niche in the biotech industry, becoming leading pioneers in iPSC research and cancer cell therapy. Even still, Century Therapeutics continues to grow, innovate, and push the boundaries of what is possible in the world of cell therapy. With patient's needs at the core, they are dedicated to developing and delivering effective, accessible, and life-changing cell therapies to those in need.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Century Therapeutics Inc. (Nasdaq: IPSC), a Philadelphia-based biotechnology company, will attend the Jefferies Global Healthcare Conference in London on November 18 to meet with investors. The company is developing off-the-shelf stem cell-derived therapies for type 1 diabetes, other autoimmune diseases, and cancer, utilizing its proprietary Allo-Evasion platform to prevent immune rejection. Interested investors can schedule one-on-one meetings with Century's management to discuss its development strategy and therapeutic pipeline.
Century Therapeutics, Inc. (NASDAQ: IPSC) announced its attendance at the 2026 Jefferies Global Healthcare Conference in London on November 18, 2026. The biotechnology company, which develops IPSC-derived cell therapies for autoimmune diseases and cancer, invites interested parties to schedule one-on-one meetings with their team during the conference. Century Therapeutics aims to advance patient access and care through its innovative Allo-Evasion™ immune evasion engineering technology.
Three healthcare companies, Century Therapeutics (IPSC), Glaukos (GKOS), and Praxis Precision Medicines (PRAX), have received bullish ratings from analysts. Piper Sandler reiterated a Buy on Century Therapeutics with a $4.00 price target. BTIG maintained Buy ratings on Glaukos with a $202.00 target and on Praxis Precision Medicines with an $826.00 target.
This article highlights bullish sentiments from three analysts regarding several healthcare companies. Edward Tenthoff of Piper Sandler reiterated a Buy rating for Century Therapeutics (IPSC) with a $4.00 price target. Ryan Zimmerman of BTIG maintained a Buy rating on Glaukos (GKOS) with a target of $202.00, and Kambiz Yazdi of BTIG also kept a Buy rating on Praxis Precision Medicines (PRAX) with an $826.00 price target.
Century Therapeutics (NASDAQ: IPSC) announced the presentation of nonclinical data for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, at the EASD 2026 meeting. The data demonstrated scalable production, in vivo function, immune evasion, and readiness for clinical testing, with the IND submission still on track for Q4 2026 and initial clinical data expected in the second half of 2027. The study showed sustained glycemic control in diabetic mouse models, consistent drug product manufacturing, and successful engraftment via the intended clinical route.